Here's where traders could go long SAVA.
The psychedelic therapeutics biotech pulled in an additional $30 million in Canadian dollars; let's figure out why and what it means -- and why it's kinda weird.
Recent news about Travelzoo and Albireo Pharma offer reasons to think those shares could be heading higher.
We are a nation divided between those who are rabid to take the vaccine and those who are not.
Let's look at how to play this biotech that provides tools for better understanding the proteome.
The simple strategy may not make for home runs but is producing a number of singles and doubles in a dicey market.
Charts suggest there could be further downside risk.
It's tough to have much confidence in this market, but a few things are working.
Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.
Let's check the charts and indicators.